

## Clarification and Response to Recent Events

PHRMA, the voice of pharmaceutical manufacturers, continues its effort to shape public opinion on the “inappropriate use of 340B”.

In a recent article published by the Tom Mirga of the 340B Report, a PHRMA spokesman is quoted to say that PHRMA “supports the original intent of the 340B program, we are concerned by the mounting evidence showing the program has strayed off course and is not helping needy patients”. What PHRMA conveniently omits is the real intent of the program, which was reaffirmed in letter sent by members of Congress to HRSA Secretary Alex Azar the September stating **“Congress clearly stated the law’s purpose: To stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”**

Although RPh Innovations strongly promotes the use of 340B as a tool for improving drug affordability. Nothing in its stated purpose suggests that 340B is limited to indigent care. We urge congress to take the steps necessary to provide the OPA the oversight power necessary to prevent drug manufacturers from redefining the purpose and scope of the program.

Please get involved, be good stewards of the program, call you legislators to ask for their support and involvement.

The RPh Innovations Team

1401 Branding Avenue, Suite 360,  
Downers Grove, Illinois 60515,  
(630) 963-0024

Website: [www.rphinnovations.com](http://www.rphinnovations.com)

Email: [rjohson@rphinnovations.com](mailto:rjohson@rphinnovations.com)

